Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion Biotech A/S (NASDAQ: EVAX) announces the appointment of Per Norlén as its new CEO, effective October 3, 2022. With over 20 years in biotech, Norlén aims to propel Evaxion's capabilities in developing AI-driven immunotherapies for cancer. He expresses confidence in the company’s potential, especially following promising phase 1 trial results in melanoma. Chairman Marianne Soegaard highlights Norlén's leadership as key to advancing the company's innovative clinical and preclinical results. Evaxion is focused on tailored therapies for cancer and other critical diseases.
Evaxion Biotech A/S (NASDAQ: EVAX) announced the enrollment of its first patient in a global Phase 2b clinical trial for EVX-01, a personalized cancer therapy targeting melanoma. This trial, conducted in collaboration with Merck, aims to evaluate the safety and efficacy of EVX-01 alongside KEYTRUDA®. Earlier Phase 1/2a data showed that 67% of patients benefited from the combination treatment, with 22% achieving complete recovery. Interim topline data is anticipated in the second half of 2023, highlighting potential advancements in melanoma treatment.
Evaxion Biotech A/S (NASDAQ: EVAX) has collaborated with UMass Chan Medical School to receive a grant from the U.S. NIH for developing a gonorrhea vaccine candidate. This initiative, part of Evaxion's EVX-B2 project utilizing their AI platform EDEN, aims to address a significant unmet medical need as gonorrhea is a critical antibiotic resistance threat. The vaccine has shown promise in preclinical studies. With the NIH grant, Evaxion intends to advance this innovative vaccine solution to combat gonorrhea infections, which currently lack effective prevention methods.
Evaxion Biotech (NASDAQ: EVAX) reported significant advancements in its immunotherapy programs during Q2 2022, including the expansion into non-small cell lung cancer and production of personalized cancer treatments for melanoma. The company identified gonorrhea as its second bacterial product target. Despite a net loss of $4.8 million and cash reserves of $25.3 million, Evaxion anticipates these funds will support development efforts for the next year. Plans to initiate a Phase 2b trial in partnership with Merck's KEYTRUDA® are also highlighted.
Evaxion Biotech A/S (NASDAQ: EVAX) announces significant executive changes, with Lars Staal Wegner resigning as CEO but staying on as an advisor. Per Norlén, M.D., Ph.D., with over 20 years in clinical drug development, has been appointed as the new CEO. Norlén's experience in oncology and leadership at biopharmaceutical companies is expected to strengthen Evaxion's management as they pursue new partnerships and consolidate future projects. Chair Marianne Soegaard expressed confidence in Norlén's ability to enhance the company's growth and benefit stakeholders.
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology firm, will announce its Q2 2022 financial results on August 10 at 8:30 a.m. EDT. The presentation will showcase the company’s progress in developing AI-driven immunotherapies for various diseases. Investors can join the call via US dial-in at +1-844-825-9789 or internationally at +1-412-317-5180 using Conference ID 10169785. An audio webcast will also be available on Evaxion’s events page.
Evaxion is based in Hørsholm, Denmark, employing around 70 staff and holding a diverse pipeline of immunotherapy candidates.
Evaxion Biotech A/S (NASDAQ: EVAX) has identified Gonorrhea as its second target for the EVX-B2 vaccine product candidate, following positive pre-clinical findings. The company's AI platform, EDEN, has pinpointed promising antigen candidates, addressing a significant unmet medical need. Gonorrhea poses serious health risks, with the CDC reporting 1.14 million new infections annually in the U.S., including 550,000 drug-resistant cases. Evaxion aims to provide a prophylactic vaccine to produce antibodies against this infection, potentially improving public health outcomes.
Evaxion Biotech A/S (NASDAQ: EVAX) announced the selection of EVX-03 as a product candidate within its DNA technology platform to target non-small cell lung cancer (NSCLC). The company plans to file for regulatory approval in H2 2022 based on positive pre-clinical results showing significant tumor reduction and a dose-response relationship. The NSCLC market is currently valued at $23 billion and projected to reach $33 billion by 2029. EVX-02 is also in the pipeline, with a phase 1/2a trial expected to read out in Q2 2023.
Evaxion Biotech A/S (NASDAQ: EVAX) announced a committed equity purchase agreement with Lincoln Park Capital Fund for up to $40 million in American Depositary Shares (ADSs) over 36 months. This agreement allows Evaxion flexibility in deciding the timing and amount of sales, thereby enhancing its financial position amid market uncertainties. As of Q1 2022, Evaxion had cash and equivalents of $31.4 million, sufficient for operations for at least 12 months without the agreement. The company is focused on advancing its personalized cancer medicines in Phase 2 clinical trials.
Inversago Pharma has appointed Glenn S. Vraniak as its new Chief Financial Officer, effective immediately. With over 20 years of experience in the life sciences sector, Vraniak previously served as CFO at Evaxion Biotech, where he led the company through a successful IPO on Nasdaq in February 2021. His extensive background includes roles at electroCore and GE Capital. CEO François Ravenelle welcomed him, anticipating his impact on Inversago's growth, particularly in developing therapies for metabolic conditions.